PMID- 16095009
OWN - NLM
STAT- MEDLINE
DCOM- 20050830
LR  - 20190911
IS  - 0300-9742 (Print)
IS  - 0300-9742 (Linking)
VI  - 34
IP  - 2
DP  - 2005 Mar-Apr
TI  - Enhanced production of macrophage inhibitory protein-1alpha in patients with 
      Behcet's disease.
PG  - 129-35
AB  - OBJECTIVE: Macrophage inhibitory protein-1alpha (MIP-1alpha), a C-C chemokine, 
      stimulates the activation and migration of leukocytes. We investigated the 
      expression of MIP-1alpha in patients with Behcet's disease (BD) and evaluated the 
      association of the MIP-1alpha levels with disease activity of BD. METHODS: Serum 
      samples were obtained from 67 BD patients and 30 healthy controls. 
      Simultaneously, whole blood cells were isolated from BD patients (n = 25) and 
      healthy controls (n = 11) and cultured in the absence or presence of 
      lipopolysaccharide (LPS), phytohaemagglutinin (PHA), and phorbol 12-myristate 
      13-acetate (PMA) plus ionomycin. The concentrations of MIP-1alpha, interleukin-8 
      (IL-8), regulated on activation, normally T cell expressed and secreted (RANTES), 
      and monocyte chemoattractant protein-1 (MCP-1) were measured in the sera and 
      culture supernatants by enzyme-linked immunosorbent assay (ELISA). RESULTS: The 
      serum levels of MIP-1alpha were higher in BD patients than in healthy controls. 
      When whole blood cells were stimulated with LPS or PMA plus ionomycin, but not 
      PHA, BD patients had higher levels of MIP-1alpha in the culture supernatants 
      compared to healthy controls. In sera and culture supernatants of whole blood 
      cells, MIP-1alpha levels correlated well with those of RANTES, MCP-1, and IL-8 in 
      BD patients. Moreover, patients with active disease had significantly higher 
      levels of serum MIP-1alpha levels compared with those with inactive disease. 
      CONCLUSION: MIP-1alpha levels were elevated in patients with BD, and correlated 
      well with IL-8, RANTES, and MCP-1 levels. These results suggest that the 
      increased MIP-1alpha levels in serum of BD patients may lead to activation and 
      migration of leukocytes, playing a role, like other chemokines, in the 
      pathogenesis of BD.
FAU - Kim, W U
AU  - Kim WU
AD  - Division of Rheumatology, Department of Internal Medicine, St. Vincent's 
      Hospital, Seoul, Korea.
FAU - Do, J H
AU  - Do JH
FAU - Park, K S
AU  - Park KS
FAU - Cho, M L
AU  - Cho ML
FAU - Park, S H
AU  - Park SH
FAU - Cho, C S
AU  - Cho CS
FAU - Kim, H Y
AU  - Kim HY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Scand J Rheumatol
JT  - Scandinavian journal of rheumatology
JID - 0321213
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL3)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Drug Combinations)
RN  - 0 (Interleukin-8)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Macrophage Inflammatory Proteins)
RN  - 0 (Phytohemagglutinins)
RN  - 56092-81-0 (Ionomycin)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Behcet Syndrome/*blood/immunology
MH  - Blood Cells/drug effects/immunology
MH  - Cells, Cultured
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL3
MH  - Chemokine CCL4
MH  - Chemokine CCL5/blood
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Interleukin-8/blood
MH  - Ionomycin/pharmacology
MH  - Lipopolysaccharides/pharmacology
MH  - Lymphocyte Activation/immunology
MH  - Macrophage Inflammatory Proteins/*blood
MH  - Male
MH  - Middle Aged
MH  - Phytohemagglutinins/pharmacology
MH  - Tetradecanoylphorbol Acetate/pharmacology
EDAT- 2005/08/13 09:00
MHDA- 2005/09/01 09:00
CRDT- 2005/08/13 09:00
PHST- 2005/08/13 09:00 [pubmed]
PHST- 2005/09/01 09:00 [medline]
PHST- 2005/08/13 09:00 [entrez]
AID - 10.1080/03009740410006943 [doi]
PST - ppublish
SO  - Scand J Rheumatol. 2005 Mar-Apr;34(2):129-35. doi: 10.1080/03009740410006943.